<code id='87252FD0D9'></code><style id='87252FD0D9'></style>
      • <acronym id='87252FD0D9'></acronym>
      <center id='87252FD0D9'><center id='87252FD0D9'><tfoot id='87252FD0D9'></tfoot></center><abbr id='87252FD0D9'><dir id='87252FD0D9'><tfoot id='87252FD0D9'></tfoot><noframes id='87252FD0D9'>
      • <optgroup id='87252FD0D9'><strike id='87252FD0D9'><sup id='87252FD0D9'></sup></strike><code id='87252FD0D9'></code></optgroup>
        5. <b id='87252FD0D9'><label id='87252FD0D9'><select id='87252FD0D9'><dt id='87252FD0D9'><span id='87252FD0D9'></span></dt></select></label></b><u id='87252FD0D9'></u>
          <i id='87252FD0D9'><strike id='87252FD0D9'><tt id='87252FD0D9'><pre id='87252FD0D9'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-29 07:35:06 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：8
                                  
                                    
          
                                   
          Bristol Myers Squibb sign
          Courtesy Bristol Myers Squibb
          Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.
          RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.
          advertisement
          Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Why some fertility treatments produce more boy babies
                                
                            
          Next article：  
                                      
                                          Heart attack and stroke risk calculators need revising
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles